Volume 30, Issue 167, January 2026

New Therapies in Atopic Dermatitis: Biologic Agents and JAK Inhibitors - A Contemporary Literature Review

Patrycja Anita Kobrzyńska^1♦, Jędrzej Mogilany², Gabriela Ragan³, Aleksandra Korżel⁴, Natalia Cegielska⁵, Karolina Górowska⁶, Julia Niedźwiecka⁷, Kamil Źródłowski⁸, Ewelina Wojna⁹

¹University Clinical Hospital No. 2 of the Medical University of Lodz: Łódź, ul. Stefana Żeromskiego 113, 90-549 Łódź, PL, Łódź, PL
²Medical University of Lodz: Lodz, Łódź Voivodeship, PL
³Medical University of Lodz, Al. Tadeusza Kościuszki 4, 90-419 Łódź, Poland
⁴Medical University of Lodz: Lodz, Łódź Voivodeship, PL
⁵Medical University of Lodz, Al. Tadeusza Kościuszki 4, 90-419 Łódź, Poland
⁶Medical University of Lodz: Lodz, Łódź Voivodeship, PL
⁷Medical University of Lodz, Al. Tadeusza Kościuszki 4, 90-419 Łódź, Poland
⁸Medical University of Lodz: Lodz, Łódź Voivodeship, PL
⁹Medical University of Lodz: Lodz, Łódź Voivodeship, PL

^♦Corresponding author
Patrycja Anita Kobrzyńska, University Clinical Hospital No. 2 of the Medical University of Lodz: Łódź, ul. Stefana Żeromskiego 113, 90-549 Łódź, PL, Łódź, PL

ABSTRACT

Atopic Dermatitis is an inflammatory skin disease characterised by ongoing inflammation and a disrupted skin barrier. Advances in our knowledge of both have made possible the use of targeted systemic therapies to treat the disease. The following is a summary of current evidence on the use of biologic agents and Janus kinase (JAK) Inhibitors as treatment options for patients with Moderate-to-Severe Atopic Dermatitis, with emphasis on their efficacy, safety, and their place in treatment plans. The Researchers conducted a narrative literature review using studies on the epidemiology and pathophysiology of atopic dermatitis, along with results from clinical trials evaluating the use of systemic biologics and JAK inhibitors for its treatment. The Researchers used PubMed to search for all relevant articles published through today describing either the use of systemic biologic or JAK Inhibitor therapy for the treatment of moderate to severe atopic dermatitis. The available data support the use of biologic treatment as the preferred option for longterm disease control across all ages. At the same time, JAK inhibitors are alternative options for patients who require additional efficacy or symptom relief sooner than would typically occur with biologic therapy. Real-world data from long-term studies will provide vital information to refine treatment protocols and enable more individualised approaches to managing moderate to severe atopic dermatitis.

Keywords: atopic dermatitis; biologics; dupilumab; tralokinumab; JAK inhibitors; abrocitinib; upadacitinib; targeted therapy; IL-4/IL-13 blockade; immunomodulation

Medical Science, 2026, 30, e15ms3803

PDF

DOI: https://doi.org/10.54905/disssi.v30i167.e15ms3803

Published: 27 January 2026